Navigation Links
Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
Date:5/1/2013

ROSEVILLE, Minn., May 1, 2013 /PRNewswire/ -- William "Bill" McGuire, M.D., former chairman and CEO of UnitedHealth Group, has joined the board of directors of Rebiotix Inc.

The Roseville, Minn.-based biotechnology company is pioneering a practical and non-antibiotic treatment for recurrent Clostridium difficile infection (CDI) known as Microbiota Restoration Therapy (MRT). CDI has been linked to 14,000 deaths annually in the US, and has become the most common healthcare-associated infection in some parts of the country, surpassing Methicillin-resistant Staphylococcus aureus (MRSA) infections. There are few evidence-based approaches to the treatment of multiple recurrent CDI.

"CDI is a major health problem with very significant implications in terms of morbidity, mortality and health resource utilization, and there are a lot of indicators that MRT could be a meaningful solution," says McGuire, who joined the Rebiotix board of directors on March 1. "The company has re-engineered fecal transplants and has brought the technology far enough down the path that it's not a pie-in-the-sky idea. There is the potential for real effectiveness here, and it's quite novel as well. It is very exciting."

Studies have shown that fecal transplant, the predecessor to MRT, is highly successful in curing recurrent CDI. However, it involves time-consuming donor screening and unappealing fecal sample preparation processes for the physician. MRT is designed to solve those problems.

The development of MRT has been spurred on by the Human Microbiome Project, a national research initiative which focused on the relationship between disease and changes in human microbial communities.

McGuire is best known for his tenure as chairman and chief executive officer of UnitedHealth Group from 1991 to 2006. He joins Rebiotix CEO Lee Jones and two other board members: longtime venture capitalist and angel investor Erwin Kelen and medical device investor/entrepreneur and former Boston Scientific/Scimed President Michael Berman .

"Bill brings not only a phenomenal medical and scientific perspective to Rebiotix, but also world-class business experience," says Jones. "His deep understanding of the healthcare system and his access to some of the very best people in the industry will help us develop the company, our technology, and the evidence to support a commercial business."

About Rebiotix
Rebiotix Inc. is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases, such as recurring Clostridium difficile infection, by harnessing the power of the human microbiome. The Roseville, Minn.-based company is pioneering practical and non-antibiotic treatments that reverse pathogenic processes and restore healthy gut flora through the transplantation of live microorganisms. For more information, visit www.Rebiotix.com.


'/>"/>
SOURCE Rebiotix Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
2. Stereotaxis Appoints William C. Mills III as Chairman of Board of Directors
3. Perrigo Company To Present At The William Blair Growth Stock Conference
4. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
5. Lippincott Williams & Wilkins Launches Electronic Health Record (EHR) Learning Tool to Help Future Nurses Prepare for New Practice Requirements
6. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
7. Aushon BioSystems Appoints Bill Williams Vice President of Sales
8. Aushon BioSystems ernennt Bill Williams zum neuen Vice President of Sales
9. BD Announces Appointment of William A. Kozy as Chief Operating Officer
10. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
11. Huntington Memorial Hospital Elects Paul Johnson, Deborah Williams to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
Breaking Medicine News(10 mins):